$631 Million is the total value of Rhenman & Partners Asset Management AB's 104 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Celgene Corp | $11,572,000 | +7.5% | 93,000 | 0.0% | 1.83% | -11.2% | |
| HCA | HCA Holdings Inc | $9,318,000 | +20.2% | 104,707 | 0.0% | 1.48% | -0.7% | |
| LBIO | Lion Biotechnologies Inc | $4,843,000 | +7.2% | 650,000 | 0.0% | 0.77% | -11.4% | |
| PTLA | Portola Pharmaceuticals Inc | $4,734,000 | +74.6% | 120,805 | 0.0% | 0.75% | +44.2% | |
| RVNC | Revance Therapeutics Inc | $4,368,000 | +0.5% | 210,000 | 0.0% | 0.69% | -16.9% | |
| RIGL | Rigel Pharmaceuticals Inc | $4,243,000 | +39.1% | 1,282,000 | 0.0% | 0.67% | +14.9% | |
| TTPH | Tetraphase Pharmaceuticals Inc | $2,757,000 | +128.0% | 300,000 | 0.0% | 0.44% | +88.4% | |
| KERX | Keryx Biopharmaceuticals Inc | $2,619,000 | +5.1% | 425,111 | 0.0% | 0.42% | -13.2% | |
| CMRX | Chimerix Inc | $2,552,000 | +38.7% | 400,000 | 0.0% | 0.40% | +14.4% | |
| CHRS | Coherus BioSciences Inc | $2,355,000 | -24.9% | 111,357 | 0.0% | 0.37% | -37.9% | |
| PODD | Insulet Corp | $1,508,000 | +14.3% | 35,000 | 0.0% | 0.24% | -5.5% | |
| BDX | Becton Dickinson & Co | $917,000 | +10.7% | 5,000 | 0.0% | 0.14% | -8.8% | |
| ACHN | Achillion Pharmaceuticals Inc | $699,000 | +1.9% | 166,000 | 0.0% | 0.11% | -15.9% | |
| CNCE | Concert Pharm Inc | $513,000 | +65.5% | 30,099 | 0.0% | 0.08% | +37.3% | |
| ADVM | Adverum Biotechnologies Inc | $416,000 | -6.9% | 154,006 | 0.0% | 0.07% | -23.3% | |
| OREXQ | Orexigen Therapeutics Inc | $413,000 | +97.6% | 120,000 | 0.0% | 0.06% | +62.5% | |
| OCUL | Ocular Therapeutix Inc | $371,000 | +10.7% | 40,000 | 0.0% | 0.06% | -7.8% | |
| MSFT | Microsoft Corp | $316,000 | +6.0% | 4,793 | 0.0% | 0.05% | -12.3% | |
| IBM | IBM Corp | $308,000 | +5.1% | 1,766 | 0.0% | 0.05% | -12.5% | |
| TNDM | Tandem Diabetes Care Inc | $281,000 | -44.1% | 234,000 | 0.0% | 0.04% | -54.2% | |
| STAA | Staar Surgical Co | $281,000 | -9.9% | 28,711 | 0.0% | 0.04% | -26.7% | |
| MRTX | Mirati Therapeutics Inc | $260,000 | +9.2% | 50,000 | 0.0% | 0.04% | -10.9% | |
| F | Ford Motor Co | $262,000 | -4.0% | 22,511 | 0.0% | 0.04% | -21.2% | |
| THLD | Threshold Pharmaceuticals | $115,000 | +29.2% | 201,537 | 0.0% | 0.02% | +5.9% | |
| OPHT | Ophthotech Corp | $88,000 | -24.1% | 23,920 | 0.0% | 0.01% | -36.4% | |
| ANTH | Anthera Pharmaceuticals Inc | $85,000 | -34.6% | 200,000 | 0.0% | 0.01% | -48.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-04-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.